Akrouf, K., Gad, A., Ibrahim, E., Kassem, M., Abdelmonem, F., Kholy, N. (2016). A Retrospective- Prospective Study for the Efficacy and Safety of Entecavir in a Cohort of West Asian with Chronic HBV Infection. Suez Canal University Medical Journal, 19(2), 201-212. doi: 10.21608/scumj.2016.116298
Kafya A Akrouf; Amal A Gad; Eman A Ibrahim; Mohamed F Kassem; Fatehia M Abdelmonem; Naglaa E Kholy. "A Retrospective- Prospective Study for the Efficacy and Safety of Entecavir in a Cohort of West Asian with Chronic HBV Infection". Suez Canal University Medical Journal, 19, 2, 2016, 201-212. doi: 10.21608/scumj.2016.116298
Akrouf, K., Gad, A., Ibrahim, E., Kassem, M., Abdelmonem, F., Kholy, N. (2016). 'A Retrospective- Prospective Study for the Efficacy and Safety of Entecavir in a Cohort of West Asian with Chronic HBV Infection', Suez Canal University Medical Journal, 19(2), pp. 201-212. doi: 10.21608/scumj.2016.116298
Akrouf, K., Gad, A., Ibrahim, E., Kassem, M., Abdelmonem, F., Kholy, N. A Retrospective- Prospective Study for the Efficacy and Safety of Entecavir in a Cohort of West Asian with Chronic HBV Infection. Suez Canal University Medical Journal, 2016; 19(2): 201-212. doi: 10.21608/scumj.2016.116298
A Retrospective- Prospective Study for the Efficacy and Safety of Entecavir in a Cohort of West Asian with Chronic HBV Infection
1Amiri Hospital, Kuwait, Thanian al Ghanem Gastrointestinal Centre, Kuwait.
2Amiri Hospital, Kuwait, Thanian al Ghanem Gastrointestinal Centre, Kuwait. Department of Internal Medicine, School of Medicine, Suez Canal University, Egypt.
3Department of Tropical Medicine, Al Azhar University, Egypt
Abstract
Aim: To assess the long-term efficacy and safety of Entecavir in the treatment of CHB. Patients and Methods: This study included 70 CHB consecutive patients on Entecavir for at least 36 months retrospectively, followed prospectively for 18 months. Results: twenty-three (32.8) were HBeAg +ve, 47.1% naive, 22 (31.4%) females, with a mean age of 42.9±13, 14 (20%) cirrhotic and 1 (1.4%) decompensated. There were no significant differences in the pre-treatment HBV-DNA level among HBeAg (+ve) and HBeAg-ve group, with a mean± SD log 10 of 7.9±5.4 and 7.4±5.0 respectively. (P= 0.237). There was a significant viral load reduction after 6 months Entecavir therapy that was more in the HBeAg –ve compared to HBeAg +ve group. In HBeAg +ve, 19 (82.61%) had HBV-DNA suppression after a median of 7 months, compared to 100% in HBeAg –ve with a median of 5 months (P <0.05). In the HBeAg-ve group; one (2.13%) had HBsAg loss at 45 months compared to none in HBeAg (+ve) group (P <0.001), while in the HBeAg (+ve) group; 5 (21.74%) showed HBeAg clearance after a median of 16 months. Multivariate analysis identified HBeAg negative status, as the only independent factor affecting viral suppression. The drug showed 100% safety. None showed hepatic decompensation, HCC or reported death. Conclusions: In real-life data; long term Entecavir treatment effectively sup-pressed HBV. Entecavir is considered an effective and safe treatment for CHB patients compared to 82% in HBeAg (+ve) group. Entecavir is considered an effective and safe choice on long term use for treatment CHB patients.
View on SCiNiTO
Top